Insilico announces nomination of preclinical candidate targeting KAT6A for ER+/HER2-

[News]

Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company's drug discovery team has nominated a preclinical candidate targeting KAT6A for ER+/HER2- breast cancer therapy utilizing its end-to-end Pharma.AI platform.

More... (https://www.news-medical.net/news/20221227/Insilico-announces-nomination-of-preclinical-candidate-targeting-KAT6A-for-ER2bHER2-breast-cancer-therapy.aspx)